Rituximab administration within 6 months of T cell-depleted allogeneic SCT is associated with prolonged life-threatening cytopenias.

Rituximab administration within 6 months of T cell-depleted allogeneic SCT is associated with prolonged life-threatening cytopenias.

Item
http://www.wikidata.org/entity/Q34164140
Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelinesRituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphomaProphylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidenceRituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial.Current status of allogeneic transplantation for aggressive non-Hodgkin lymphoma.Recent progress in managing graft-versus-host disease and viral infections following allogeneic stem cell transplantation.EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT.Predictors of outcome in reduced intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: summarizing the evidence and highlighting the limitations.Greatly reduced risk of EBV reactivation in rituximab-experienced recipients of alemtuzumab-conditioned allogeneic HSCT.Immunologic recovery in children after alternative donor allogeneic transplantation for hematologic malignancies: comparison of recipients of partially T cell-depleted peripheral blood stem cells and umbilical cord blood.Risk factors for post-transplant lymphoproliferative disorder after Thymoglobulin-conditioned hematopoietic cell transplantation.
P2860

Rituximab administration within 6 months of T cell-depleted allogeneic SCT is associated with prolonged life-threatening cytopenias.

Item
http://www.wikidata.org/entity/Q34164140
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Rituximab administration withi ...... d life-threatening cytopenias.
@ast
Rituximab administration withi ...... d life-threatening cytopenias.
@en
Rituximab administration withi ...... d life-threatening cytopenias.
@nl
type
label
Rituximab administration withi ...... d life-threatening cytopenias.
@ast
Rituximab administration withi ...... d life-threatening cytopenias.
@en
Rituximab administration withi ...... d life-threatening cytopenias.
@nl
prefLabel
Rituximab administration withi ...... d life-threatening cytopenias.
@ast
Rituximab administration withi ...... d life-threatening cytopenias.
@en
Rituximab administration withi ...... d life-threatening cytopenias.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P5875
P698
P932
P356
P1433
P1476
Rituximab administration withi ...... d life-threatening cytopenias.
@en
P2093
P2860
P304
P31
P356
10.1016/J.BBMT.2010.05.004
P433
P478
P577
P5875
P698
P932